Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

PURPOSE: Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North Central Cancer Treatm...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Perez, Edith A., Romond, Edward H., Suman, Vera J., Jeong, Jong-Hyeon, Davidson, Nancy E., Geyer, Charles E., Martino, Silvana, Mamounas, Eleftherios P., Kaufman, Peter A., Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3164242/
https://ncbi.nlm.nih.gov/pubmed/21768458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.0868
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares